| Tchem | Tyrosine-protein phosphatase non-receptor type 11 |
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are a cause of Noonan syndrome as well as acute myeloid leukemia. [provided by RefSeq, Aug 2016]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| lung adenocarcinoma | 2714 | 3.46568382145693E-17 |
| osteosarcoma | 7933 | 6.97203179321468E-8 |
| breast carcinoma | 1614 | 8.32021905637698E-5 |
| oligodendroglioma | 2849 | 3.80168832092699E-4 |
| medulloblastoma, large-cell | 6234 | 8.82309487668874E-4 |
| Pick disease | 1893 | 0.00113802412310452 |
| ependymoma | 2514 | 0.00177385416171052 |
| adult high grade glioma | 2148 | 0.00331055117333534 |
| progressive supranuclear palsy | 674 | 0.00367222568265501 |
| Down syndrome | 548 | 0.00451682912104919 |
| hereditary spastic paraplegia | 313 | 0.00494600400193201 |
| dermatomyositis | 967 | 0.0059079800413174 |
| astrocytic glioma | 2241 | 0.0064397037886553 |
| Gaucher disease type 1 | 171 | 0.013370080399036 |
| pancreatic ductal adenocarcinoma liver metastasis | 1795 | 0.0204367225461519 |
| Multiple myeloma | 1328 | 0.0246277528787756 |
| glioblastoma | 5572 | 0.0292582223719261 |
| group 4 medulloblastoma | 1875 | 0.0487576401199113 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Celiac disease | 112 | 0.0 | 2.0 |
| Hemolytic anemia | 70 | 0.0 | 2.0 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Cancer | 2346 | 5.317 | 2.7 |
| Pulmonary valve stenosis | 10 | 5.104 | 2.6 |
| Hypertrophic Cardiomyopathy | 56 | 4.837 | 2.4 |
| Congenital heart disease | 63 | 4.788 | 2.4 |
| Neurofibromatosis | 37 | 4.154 | 2.1 |
| Cryptorchidism | 67 | 3.869 | 1.9 |
| Gastritis | 44 | 3.504 | 1.8 |
| Exostosis | 15 | 3.099 | 1.5 |
| Cystic lymphangioma | 14 | 3.088 | 1.5 |
| Juvenile xanthogranuloma | 6 | 3.085 | 1.5 |
| Cherubism | 14 | 3.039 | 1.5 |
| Disease | Target Count |
|---|---|
| Leukemia, juvenile myelomonocytic | 7 |
| Disease | log2 FC | p |
|---|---|---|
| Multiple myeloma | 1.196 | 0.025 |
| astrocytic glioma | 1.400 | 0.006 |
| ependymoma | 1.500 | 0.002 |
| oligodendroglioma | 1.800 | 0.000 |
| osteosarcoma | 2.945 | 0.000 |
| glioblastoma | 1.200 | 0.029 |
| medulloblastoma, large-cell | 1.300 | 0.001 |
| hereditary spastic paraplegia | -1.204 | 0.005 |
| pancreatic ductal adenocarcinoma liver m... | -1.691 | 0.020 |
| breast carcinoma | -1.100 | 0.000 |
| adult high grade glioma | -1.500 | 0.003 |
| group 4 medulloblastoma | 1.300 | 0.049 |
| lung adenocarcinoma | -1.500 | 0.000 |
| Pick disease | -1.100 | 0.001 |
| progressive supranuclear palsy | -1.400 | 0.004 |
| Gaucher disease type 1 | -1.300 | 0.013 |
| Down syndrome | 1.400 | 0.005 |
| dermatomyositis | -1.100 | 0.006 |
| Species | Source |
|---|---|
| Chimp | OMA EggNOG |
| Macaque | OMA EggNOG Inparanoid |
| Mouse | OMA EggNOG Inparanoid |
| Rat | OMA EggNOG Inparanoid |
| Dog | OMA EggNOG Inparanoid |
| Cow | OMA EggNOG Inparanoid |
| Pig | OMA EggNOG Inparanoid |
| Opossum | OMA EggNOG Inparanoid |
| Chicken | OMA Inparanoid |
| Anole lizard | OMA Inparanoid |
CHEMBL502013
pIC50 6.00
CHEMBL3319361
pIC50 6.07
CHEMBL526644
pIC50 6.10
CHEMBL3319360
pIC50 6.11
CHEMBL3319359
pIC50 6.12
CHEMBL3693872
pIC50 6.16
CHEMBL1765357
pKi 6.16
CHEMBL3319358
pIC50 6.18
CHEMBL3319381
pIC50 6.20
CHEMBL3319357
pIC50 6.21
CHEMBL2316908
pIC50 6.22
CHEMBL2396718
pIC50 6.25
CHEMBL3609373
pKi 6.29
CHEMBL459711
pIC50 6.35
CHEMBL3319380
pIC50 6.38
CHEMBL3319379
pIC50 6.42
CHEMBL3319378
pIC50 6.43
CHEMBL3692124
pIC50 6.50
CHEMBL472004
pIC50 6.50
CHEMBL501993
pIC50 6.50
| PMID | Text |
|---|---|
| 27030275 | Combined X-ray crystallography, small-angle X-ray scattering, and biochemistry to elucidate structural and mechanistic features of three cancer-associated SHP2 variants with single point mutations within the N-SH2:PTP interdomain autoinhibitory interface. |
| 26755576 | find that Shp2 is distributed to the kinetochore, centrosome, spindle midzone, and midbody |
| 26742426 | We found that LS-associated SHP2 mutants (Y279C, T468M, Q506P, and Q510E) exhibited a substantially reduced phosphatase activity toward parafibromin when compared with wild-type SHP2. |
| 26728598 | The existence of a tight association between SHP2 and EGFR expression in tumors and cell lines further suggested the importance of SHP2 in EGFR expression. |
| 26617336 | SHP2 preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signaling. |
| 26556238 | SHP-2 co-localized with the Cryptosporidium parvum sporozoite and this interaction increased the rate of C. parvum infectivity through SH2-mediated SHP-2 activity in intestinal epithelial cells. |
| 26385178 | a decrease in PTEN facilitates ROS/SHP2 signaling, causing lung cancer cells to become unresponsive to IFN-gamma |
| 26365186 | PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. |
| 26315028 | protein tyrosine phosphatase non-receptor type 1 and type 2 are potential therapeutic targets for breast cancer stem cells and gamma-T3 is a promising natural drug for future breast cancer therapy. |
| 26286251 | mutation in PTPN11 is associated with co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome. |
| More... |
MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEK 1 - 70 FATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRES 71 - 140 QSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVL 141 - 210 QLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYK 211 - 280 NILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENS 281 - 350 RVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQALLQGNTERTVW 351 - 420 QYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDC 421 - 490 DIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGD 491 - 560 QSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR 561 - 597 //
| PMID | Year | Title |
|---|---|---|
| 27030275 | 2016 | Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2. |
| 26755576 | 2016 | Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. |
| 26742426 | 2016 | Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling. |
| 26728598 | 2016 | SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. |
| 26617336 | 2015 | Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. |
| 26556238 | 2015 | SHP-2 Mediates Cryptosporidium parvum Infectivity in Human Intestinal Epithelial Cells. |
| 26385178 | 2015 | Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-?. |
| 26365186 | 2015 | PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. |
| 26315028 | 2015 | Gamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway. |
| 26286251 | 2015 | Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11. |
| More... |
